Table 1.
Univariable Cox proportional hazard analysis of relationship between clinical variables and recurrence-free survival
| Recurrence-free survival | ||||||
|---|---|---|---|---|---|---|
| Variable | Number of patients | Number of events | P value | Hazard ratio | 95 % CI | |
| Tumor (T) stage prior to NAC | 0.731 | |||||
| T1 | 28 | 1 | ||||
| T2 | 149 | 19 | 2.42 | 0.32, 18.16 | ||
| T3 | 79 | 12 | 2.7 | 0.35, 20.99 | ||
| T4 | 16 | 3 | 2.91 | 0.30, 28.09 | ||
| Node (N) stage prior to NAC | 0.558 | |||||
| Negative | 55 | 6 | ||||
| Positive | 217 | 29 | 1.29 | 0.54, 3.11 | ||
| Clinical stage | 0.847 | |||||
| II | 185 | 24 | ||||
| III | 86 | 11 | 0.93 | 0.46, 1.91 | ||
| Unknown | 1 | |||||
| Age | 0.008 | |||||
| ≤50 years at diagnosis | 177 | 17 | ||||
| >50 years at diagnosis | 95 | 18 | 2.49 | 1.28, 4.85 | ||
| Menopausal status | 0.017 | |||||
| Premenopausal | 161 | 15 | ||||
| Perimenopausal | 16 | 2 | 1.42 | 0.32, 6.24 | ||
| Postmenopausal | 91 | 18 | 2.74 | 1.38, 5.46 | ||
| Unknown | 4 | |||||
| Histologya | 0.835 | |||||
| Adenocarcinoma, n | 18 | 3 | ||||
| Ductal carcinoma | 207 | 27 | 1.39 | 0.42, 4.62 | ||
| Lobular carcinoma | 39 | 4 | 0.93 | 0.21, 4.16 | ||
| Other | 8 | 1 | 1.08 | 0.11, 10.42 | ||
| Progesterone receptora | 0.199 | |||||
| Negative | 76 | 13 | ||||
| Positive | 192 | 21 | 0.63 | 0.31, 1.26 | ||
| Unknown | 4 | |||||
| Tumor gradea | 0.14 | |||||
| Good | 28 | 2 | ||||
| Moderate | 117 | 16 | 3.57 | 0.8, 15.93 | ||
| Poor | 32 | 5 | 3.52 | 0.66, 18.73 | ||
| Unknown | 95 | |||||
| Chemotherapy regimen | 0.89 | |||||
| ddAC | 167 | 20 | ||||
| AC-CD | 77 | 8 | 1.23 | 0.54, 2.83 | ||
| AD | 14 | 4 | 0.79 | 0.25, 2.55 | ||
| CD | 13 | 3 | 1.33 | 0.39, 4.51 | ||
| Unknown | 1 | |||||
| Pathologic response | ||||||
| ypT0/isypN0: | No | 261 | 35 | 0.41 | ||
| yes | 11 | 0 | 0.37 | 0, −b | ||
| ypT0/is: | No | 251 | 34 | 0.29 | ||
| yes | 21 | 1 | 0.39 | 0.05, 2.88 | ||
| ypT < mic: | No | 221 | 28 | 0.91 | ||
| yes | 51 | 7 | 0.95 | 0.42, 0.91 | ||
Univariable Cox model for clinical and pathologic parameters of recurrence-free survival. aDetermined on pre-chemotherapy ultrasound-guided biopsy. b− CI boundary could not be estimated. NAC neoadjuvant chemotherapy, CI confidence interval , (dd)AC (dose-dense) cyclophosphamide and doxorubcin, CD capecitabine and docetaxel, AD doxorubcin and docetaxel, ypT0/isypN0 no residual invasive tumor in breast and axilla, ypT0/is no residual invasive tumor in the breast, ypT < mic few scattered tumor cells in the breast. Numbers in bold are significant values